Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors

• Published in: Clinical cancer research 2016-10, Vol.22 (19), p.4837-4847
• Main Authors: Ortiz-Cuaran, Sandra, Scheffler, Matthias, Plenker, Dennis, Dahmen, Llona, Scheel, Andreas H, Fernandez-Cuesta, Lynnette, Meder, Lydia, Lovly, Christine M, Persigehl, Thorsten, Merkelbach-Bruse, Sabine, Bos, Marc, Michels, Sebastian, Fischer, Rieke, Albus, Kerstin, König, Katharina, Schildhaus, Hans-Ulrich, Fassunke, Jana, Ihle, Michaela A, Pasternack, Helen, Heydt, Carina, Becker, Christian, Altmüller, Janine, Ji, Hongbin, Müller, Christian, Florin, Alexandra, Heuckmann, Johannes M, Nuernberg, Peter, Ansén, Sascha, Heukamp, Lukas C, Berg, Johannes, Pao, William, Peifer, Martin, Buettner, Reinhard, Wolf, Jürgen, Thomas, Roman K, Sos, Martin L
• Format: Article
• Language: English
• Subjects: Acrylamides - therapeutic use; Adenocarcinoma - drug therapy; Adenocarcinoma of Lung; Aged; Aniline Compounds - therapeutic use; Antineoplastic Agents - therapeutic use; Drug Resistance, Neoplasm - genetics; ErbB Receptors - antagonists & inhibitors; Female; Humans; Lung Neoplasms - drug therapy; Male; Middle Aged; Pyrimidines - therapeutic use
• ISSN: 1078-0432; 1557-3265
• DOI: 10.1158/1078-0432.ccr-15-1915

To identify novel mechanisms of resistance to third-generation EGFR inhibitors in patients with lung adenocarcinoma that progressed under therapy with either AZD9291 or rociletinib (CO-1686). We analyzed tumor biopsies from seven patients obtained before, during, and/or after treatment with AZD9291 or rociletinib (CO-1686). Targeted sequencing and FISH analyses were performed, and the relevance of candidate genes was functionally assessed in in vitro models. We found recurrent amplification of either MET or ERBB2 in tumors that were resistant or developed resistance to third-generation EGFR inhibitors and show that ERBB2 and MET activation can confer resistance to these compounds. Furthermore, we identified a KRAS mutation in a patient with acquired resistance to AZD9291 as a potential driver of acquired resistance. Finally, we show that dual inhibition of EGFR/MEK might be a viable strategy to overcome resistance in EGFR-mutant cells expressing mutant KRAS CONCLUSIONS: Our data suggest that heterogeneous mechanisms of resistance can drive primary and acquired resistance to third-generation EGFR inhibitors and provide a rationale for potential combination strategies. Clin Cancer Res; 22(19); 4837-47. ©2016 AACR.